"Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions"-Treatment of ALL.

The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible, whereas in standard-risk patients this procedure should be avoided also in light of related toxicity and because there are no significant benefits. Furthermore, better characterization of the molecular genetic events can drive therapeutic decisions: a historical example in this respect is represented by the use of tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome-positive ALL; in the upcoming future, TKIs might be used also in other subgroups, such as breakpoint cluster region/Abelson 1-like cases and others with deregulated tyrosine kinases. Finally, the greatest progress is currently achieved with new immunotherapies targeting frequently expressed surface antigens in ALL. It is also a new chance for elderly ALL patients, so far spared from intensive chemotherapy and allo-SCT. These targeted therapies will substantially change this treatment algorithm and the great challenge is to find optimal sequence of the extended therapy options in an individual patient

Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML

The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second generation of FDA-approved ABL tyrosine kinase inhibitors, dasatinib and nilotinib, are more potent inhibitors of BCR-ABL1 kinase in vitro. Originally approved for the treatment of patients who were refractory to or intolerant of imatinib, dasatinib and nilotinib are now also FDA approved in the first-line setting. The choice of tyrosine kinase inhibitor (ie, standard or high dose imatinib, dasatinib, nilotinib) to use for initial therapy in chronic-phase CML (CML-CP) will not always be obvious. Therapy selection will depend on both clinical and molecular factors, which we will discuss in this review

Conducting Polymer and Hydrogenated Amorphous Silicon Hybrid Solar Cells

An organic-inorganic hybrid solar cell with a p-i-n stack structure has been investigated. The p-layer was a spin coated film of PEDOT:PSS poly 3,4-ethylenedioxythiophene polystyrenesulfonate. The i-layer was hydrogenated amorphous silicon a-Si:H, and the n-layer was microcrystalline silicon c-Si. The inorganic layers were deposited on top of the organic layer by the hot-wire chemical vapor deposition technique at 200 °C. These hybrid devices exhibited open circuit voltages VOC as large as 0.88 V and solar conversion efficiencies as large as 2.1%. Comparison of these devices with those incorporating a-SiC:H:B p-layers indicates that the organic layer is acting as an electrically ideal p-layer

Efecto de la inclusión de un hidrolizado de mucosa digestiva porcina (palbio 50 rd®) en piensos de broilers con niveles diferentes de lisina

La alimentación del pollo broiler durante la primera semana de vida es de creciente importancia debido a que la edad de sacrificio ha disminuido de forma constante en los últimos años. Además, consumos elevados durante la primera semana de vida mejoran el desarrollo del aparato digestivo de las aves, favoreciendo el crecimiento de las vellosidades intestinales y la eficiencia alimenticia (Lilburn, 1998, Noy et al., 2005). En los últimos años, el mercado dispone de nuevos productos de origen animal obtenidos durante el proceso de obtención de la heparina para uso farmacéutico. Uno de estos productos comerciales (Palbio 50 RD, Bioibérica S.A., Palafolls, Barcelona) está formado por la proteína hidrolizada de la mucosa digestiva de porcino limpia de contenidos intestinales, secada mediante un procedimiento especial que incluye la utilización de harina de soja como excipiente. Recientes estudios han demostrado de forma fehaciente el interés de utilizar este ingrediente en piensos de lechones de primera edad (Lindeman, et al., 2000; Corassa et al., 2007) pero los datos existentes en aves son más limitados. El objetivo de esta investigación fue evaluar los efectos de niveles crecientes de este hidrolizado proteico (PAL) sobre la productividad de pollos que recibían piensos con dos niveles diferentes de lisina total (Lys

Growth response of broiler chickens to inclusion of hydrolyzed porcine mucosa (Palbio) in diets varying in total lysine content.

Growth response of broiler chickens to inclusion of hydrolyzed porcine mucosa (Palbio) in diets varying in total lysine conten

Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report

<p>Abstract</p> <p>Introduction</p> <p>Due to high rates of response and durable remissions, imatinib (Glivec^®, or Gleevec^® in the USA; Novartis Pharma AG) is the standard of care in patients with chronic myeloid leukemia. Recently, a non-authorized product which claims comparability to imatinib has become available.</p> <p>Case presentation</p> <p>This report describes the loss of response in a 36-year-old male patient with chronic-phase chronic myeloid leukemia who had previously been in full hematologic and cytogenetic remission and partial molecular remission for three years, under treatment with brand-name imatinib of 400 mg per day. Before the initiation of treatment with a copy product, imatib (CIPLA-India), the patient had negative BCR-ABL status. Within three months of initiation of treatment with the copy product, the patient's BCR-ABL status became positive, with substantial decreases noted in white blood cell counts, red blood cell counts and platelet counts. Conversion of the BCR-ABL status to negative and improvements in hematologic parameters were achieved when the brand medication, imatinib, was resumed at a dose of 600 mg per day.</p> <p>Conclusion</p> <p>In our patient, the substitution of a copy product for imatinib resulted in the rapid loss of a previously stable response, with the risk of progression to life-threatening accelerated phase or blast crisis phase of the disease. Without supportive clinical evidence of efficacy and safety of imatib (or any other copy product) caution should be used when substituting imatinib in the treatment of any patient with chronic myeloid leukemia.</p